Introduction: Findings from randomized controlled trials require contextualization within real-life clinical practice and in broader patient populations. This study examined clinical outcomes of budesonide/glycopyrrolate/formoterol fumarate (BGF) among patients with COPD from a large general practice database in the United Kingdom.

Aims and objectives:To describe medication success after BGF initiation among patients with COPD.

Methods: New persistent (?2 prescriptions) users of BGF were identified in the Optimum Patient Care Research Database (OPCRD). Patients were followed from BGF initiation until 24/10/2022 or death. The binary, composite outcome of medication success was assessed at 90 (primary outcome; early success) and 180 (exploratory outcome) days after BGF initiation and defined as lack of pneumonia or any major cardiac or respiratory event (complicated COPD exacerbations [requiring hospitalization, or more than initial treatment with oral steroids and/or antibiotics for an exacerbation], myocardial infarction, new/hospitalized heart failure, and death). Medication success was claimed if the lower 95% confidence interval (CI) for the proportion of patients meeting the primary outcome was ?70%.

Results: 285 patients receiving ?2 BGF prescriptions were included. Early (90-day) medication success was achieved for 275 patients (96.5%, 95% CI: 93.6, 98.3). At 180 days, medication success was achieved for 169 of 184 patients with this length of follow-up (91.8%, 95% CI: 86.9, 95.4).

Conclusions: Patients initiating BGF experienced high levels of real-life medication sucesss & protection against adverse cardiopulmonary events